Methylation of the MGMT promoter is seen as lower in frequency at around 35–45% of the cases of malignant gliomas (WHO grades III and IV), while it appears in approximately 80% of low-grade gliomas (WHO grade II) [20,21]. The gene discussed is MGMT; the disease is central nervous system cancer.